HIV protease inhibitors: Antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 207-211

  Monini, Paolo ^a   Sgadari, Cecilia ^a   Barillari, Giovanni ^a   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HIV; Protease inihibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIRETROVIRUS AGENT; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDINAVIR; INTEGRIN; INTERLEUKIN 6; INTERLEUKIN 8; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TUMOR NECROSIS FACTOR ALPHA;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG SPECIFICITY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IMMUNOMODULATION; KAPOSI SARCOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 0037329153     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg086     Document Type: Article

References (31)

1. Deeks, S. G., Smith, M., Holodniy, M. & Kahn, J. O. (1997). HIV-1 protease inhibitors. A review for clinicians. Journal of the American Medical Association 277, 145-53.
2. Powderly, W. G. (2002). Long-term exposure to lifelong therapies. Journal of Acquired Immune Deficiency Syndromes 29, Suppl. 1, S28-40.
3. Boshoff, C. & Weiss, R. (2002). AIDS-related malignancies. Nature Reviews Cancer 2, 373-82.
4. Sgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S. et al. (2002). HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Medicine 8, 225-32.
5. International Collaboration on HIV and Cancer. (2000). Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. Journal of the National Cancer Institute 92, 1823-30.
6. Cattelan, A. M., Calabro, M. L., Aversa, S. M., Zanchetta, M., Meneghetti, F., De Rossi, A. et al. (1999). Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. European Journal of Cancer 35, 1809-15.
7. Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L. et al. (1987). The efficacy of aziothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 317, 185-91.
8. Zucker, S. D., Qin, X., Rouster, S. D., Yu, F., Green, R. M., Keshavan, P. et al. (2001). Mechanism of indinavir-induced hyperbilirubinemia. Proceedings of the National Academy of Sciences, USA 98, 12671-6.
9. Liang, J. S., Distler, O., Cooper, D. A., Jamil, H., Deckelbaum, R. J., Ginsberg, H. N. et al. (2001). HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Medicine 7, 1327-31.
10. Murata, H., Hruz, P. W. & Mueckler, M. (2002). Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16, 859-63.
11. Jain, R. G. & Lenhard, J. M. (2002). Select HIV protease inhibitors alter bone and fat metabolism ex vivo. Journal of Biochemical Chemistry 277, 19247-50.
12. Phenix, B. N., Lum, J. J., Nie, Z., Sanchez-Dardon, J. & Badley, A. D. (2001). Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 98, 1078-85.
13. Chavan, S., Kodoth, S., Pahwa, R. & Pahwa, S. (2001). The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 98, 383-9.
14. Pati, S., Pelser, C. B., Dufraine, J., Bryant, J. L., Reitz, M. S., Jr & Weichold, F. F. (2002). Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99, 3771-9.
15. Andre, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Jr, Cerundolo, V. et al. (1998). An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proceedings of the National Academy of Sciences, USA 95, 13120-4.
16. Tovo, P. A. (2000). Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects. AIDS 14, 743-4.
17. Gruber, A., Wheat, J. C., Kuhen, K. L., Looney, D. J. & Wong-Staal, F. (2001). Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. Journal of Biological Chemistry 276, 47840-3.
18. Cassone, A., Tacconelli, E., De Bernardis, F., Tumbarello, M., Torosantucci, A., Chiani, P. et al. (2002). Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. Journal of Infectious Diseases 185, 188-95.
19. Ensoli, B., Gendelman, R., Markham, P., Fiorelli, V., Colombini, S., Raffeld, M. et al. (1994). Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371, 674-80.
20. Ensoli, B., Sturzl, M. & Monini, P. (2001). Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Advances in Cancer Research 81, 161-200.
21. Kedes, D. H. & Ganem, D. (1997). Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. Journal of Clinical Investigation 99, 2082-6.
22. Sirianni, M. C., Vincenti, L., Topino, S., Giovannetti, A., Mazzetta, F., Libi, F. et al. (2002). NK cell activity controls human herpesvirus 8 latent infection and is restored upon HAART in AIDS patients with regressing Kaposi's sarcoma. European Journal of Immunology 32, 2711-20.
23. Egeblad, M. & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2, 161-74.
24. Toschi, E., Barillari, G., Sgadari, C., Bacigalupo, I., Cereseto, A., Carlei, D. et al. (2001). Activation of matrix-metalloproteinase-2 and membrane-type-1 -matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Molecular Biology of the Cell 12, 2934-46.
25. Goldberg, A. L. & Rock, K. (2002). Not just research tools-proteasome inhibitors offer therapeutic promise. Nature Medicine 8, 338-40.
26. Piccinini, M., Rinaudo, M. T., Chiapello, N., Ricotti, E., Baldovino, S., Mostert, M. et al. (2002). The human 26S proteasome is a target of antiretroviral agents. AIDS 16, 693-700.
27. Kelleher, A. D., Booth, B. L., Jr, Sewell, A. K., Oxenius, A., Cerundolo, V., McMichael, A. J. et al. (2001). Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes. AIDS Research and Human Retroviruses 17, 1063-6.
28. Lopez, D., Gil-Torregrosa, B. C., Bergmann, C. & Del Val, M. (2000). Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation. Journal of Immunology 164, 5070-7.
29. Kobayashi, Y., Matsumoto, M., Kotani, M. & Makino, T. (1999). Possible involvement of matrix metalloproteinase-9 in Langerhans cell migration and maturation. Journal of Immunology 163, 5989-93.
30. Martignetti, J. A., Aqeel, A. A., Sewairi, W. A., Boumah, C. E., Kambouris, M., Mayouf, S. A. et al. (2001). Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nature Genetics 28, 261-5.
31. Ikebe, T., Takeuchi, H., Jimi, E., Beppu, M., Shinohara, M. & Shirasuna, K. (1998). Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. International Journal of Cancer 77, 578-85.